Xin Lang Cai Jing·2025-12-18 06:00Core Viewpoint - Nocera Biopharma's stock has experienced a significant decline recently, despite a strong year-to-date performance, indicating potential volatility in the market [1][2]. Group 1: Company Overview - Nocera Biopharma, established on November 3, 2015, and listed on September 21, 2022, is primarily engaged in the research, production, and commercialization of biopharmaceuticals, focusing on unmet clinical needs in oncology and autoimmune diseases [2]. - The company's revenue composition includes 87.67% from drug sales, 12.04% from technology licensing, and 0.15% each from testing and research services [2]. - Nocera Biopharma operates mainly in China and the United States, with a product pipeline that includes ICP-022, ICP-B04, ICP-490, ICP-192, and ICP-723 [2]. Group 2: Financial Performance - For the period from January to September 2025, Nocera Biopharma reported a revenue of 1.115 billion yuan, reflecting a year-on-year growth of 59.85%, while the net profit attributable to shareholders was -64.41 million yuan, an increase of 76.61% year-on-year [2]. - The company's stock price has increased by 78.99% year-to-date, but it has seen declines of 7.76% over the last five trading days, 9.06% over the last 20 days, and 18.29% over the last 60 days [1]. Group 3: Shareholder Information - As of September 30, 2025, Nocera Biopharma had 16,500 shareholders, an increase of 8.66% from the previous period [2]. - The top ten circulating shareholders include various funds, with notable changes such as a decrease in holdings by 富国精准医疗灵活配置混合A and new entries like 万家优选 and 平安医疗健康混合A [3].